Combating Q fever requires development of Q fever vaccines and therapies and such development is a critical and an innovative domain. Our company being a research service provider professionally is ready to step forward and open up this domain so that great solutions towards combating Q fever will be available.
Overview of Q Fever
Q fever or query fever is the zoonotic disease caused by the intracellular bacterium Q fever which is associated with domestic animals such as cattle, sheep, and goats. Major means of transmission encompasses the inhalation of aerosolized particles or contact with animal products such as milk, urine, feces or reproductive fluids. The period between exposure and development of the clinical disease is between 9 to 40 days, during which most of the symptomatic cases present with respiratory flu. If left untreated, the atypical pneumonia develops into endocarditis which is life-threatening, on the other hand the disease can also lead to long term repercussions.
Fig.1 Landmark events in Q fever research. (Redden P., et al., 2023)
Vaccine Development for Q Fever
Historical Vaccines
The history of the Q Fever vaccine traces back to virulent egg-yolk membrane based whole cell vaccines. In this regard, the Henzerling vaccine will be noted as being protective, but it produced inflammation at the site of injection.
Current Vaccines
The most sophisticated and legalised vaccine is Q-VAX, a whole cell vaccine formalin killed which offers fundamental protection but needs precautionary vaccination screening to reduce the risk of causing harm to individuals who have been exposed previously.
Therapeutics Development for Q Fever
Antibiotic Therapies
According to reports, people suffering from Q Fever require the use of antibiotics and in acute cases Doxycycline has been seen as a first-line option. Additionally, there are chronic forms of endocarditis which require the use of hydroxy choroquine in tandem with doxycycline for a treatment period lasting from 18 to 24 months.
Novel Therapies
Currently, efforts are being directed towards formulating new therapeutics strategies targeting C. burnetii more efficiently. This includes the exploration of pharmacological agents that inhibit the pathogen survival inside the eukaryotic cells as well as engineering phage therapies for the specific elimination of the pathogen.
Our Services
Our company is at the forefront of Q fever vaccine and therapy development, thanks to the extensive expertise we have in infectious disease research. We take pride in our services which are tailored towards a robust research and development initiative with the overall aim of developing possible vaccines along with therapeutics for Q fever.
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
Disease Models
- BALB/c Mouse Models
- C57Bl/6 Mouse Models
- A/J Mouse Models
- HLA-DR Transgenic Mouse Models (B/6 background)
- Non-Human Primate (NHP) Models
Any prospective candidates for a vaccine undergo extensive preclinical analysis that we conduct, in addition to utilizing core immunology and molecular biology engineering. Our research abilities are also enhanced by our partnerships with schools and companies. Get in touch with us, if you would like to avail our services.
References
- Redden, Patricia, et al. "Q fever–immune responses and novel vaccine strategies." Future Microbiology 18.16 (2023): 1185-1196.
- Navaei, Hossein. "Q fever: etiology, diagnosis, and treatment." Journal of Zoonotic Diseases 7.2 (2023): 260-274.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
